Echinomycin

Summary

Echinomycin is a cyclic depsipeptide (quinoxaline) antibiotic produced by Streptomyces species. It belongs to the bisintercalator family, binding DNA at two sites and has been investigated as an antitumor agent and as a direct inhibitor of hypoxia‑inducible factor‑1 (HIF‑1) transcriptional activity. Research has progressed from biosynthetic studies to early‑phase clinical trials, but the compound remains in the experimental stage.

Mechanism of Action

Echinomycin contains two planar quinoxaline rings that insert between adjacent base pairs of double‑stranded DNA, a process called bis‑intercalation. This stabilises the DNA duplex and blocks the binding of transcription factors, notably HIF‑1, thereby preventing transcription of hypoxia‑responsive genes. The drug’s cytotoxicity is linked to this interference with DNA‑dependent processes, leading to cell‑cycle arrest and apoptosis in rapidly dividing tumor cells.

What the Research Shows

Reviews describe echinomycin as a prototypical bis‑intercalator with antiviral, antibacterial and anticancer properties (Zolova et al., 2010). Biosynthetic work has reconstituted its non‑ribosomal peptide synthetase pathway in E. coli and identified enzymes that form its disulfide bridge (Sato et al., 2013). Early animal studies showed dose‑dependent gastrointestinal, hepatic and lymphoreticular toxicity after intravenous dosing in mice and dogs (Foster et al., 1985). Phase I clinical trials conducted by the National Cancer Institute reported nausea, vomiting, reversible liver enzyme elevations and allergic reactions, prompting Phase II evaluation in multiple cancers. More recent reviews list echinomycin as a direct HIF‑1 inhibitor, highlighting its ability to block HIF‑1 DNA binding (Wang et al., 2011).

Reported Benefits

Preclinical models demonstrated potent antitumor activity against murine melanoma and leukemia, attributed to DNA bis‑intercalation and HIF‑1 inhibition. The unique dual‑intercalating structure offers a mechanistic approach distinct from conventional chemotherapeutics, and its ability to suppress hypoxia‑driven transcription suggests potential synergy with radiotherapy and other agents. The biosynthetic pathway has been elucidated, enabling engineered analog development.

Limitations of the Evidence

Clinical development has been hampered by significant toxicity, especially gastrointestinal, hepatic and lymphoreticular effects, which were dose‑limiting in animal studies and caused nausea, vomiting and liver enzyme changes in humans. No regulatory approval has been granted; the compound remains investigational. Evidence for efficacy is limited to early‑phase trials and animal models, and the therapeutic window appears narrow. Data on long‑term outcomes and comparative effectiveness are lacking.

Safety Considerations

Intravenous administration in animals produced reversible damage to the gastrointestinal tract, liver and lymphoid tissues, with higher doses causing persistent injury. Human Phase I trials reported common adverse events of nausea, vomiting, transient elevations in liver enzymes and occasional allergic reactions. Toxicities were generally reversible except at the highest doses. Careful monitoring of hepatic function and supportive care for gastrointestinal symptoms would be essential in any future studies.

How It Is Administered

Echinomycin has been administered exclusively by intravenous injection in preclinical and early clinical studies, using single bolus doses or daily infusions over several days. Formulations described in the literature are aqueous solutions suitable for IV infusion. No oral or alternative routes have been reported.

Routes of Administration

Goals & Uses

• Pediatric leukemia treatmentOncologyLow
• Antimicrobial activityAnti InfectiveLow
• Anticancer activity (leukemia, lymphoma)OncologyLow
• Hypoxia‑targeted therapyResearchLow
• HIF-1alpha inhibition in solid tumorsOncology / Hypoxia TargetingLow
• Solid tumor anticancer therapyOncologyModerate

Contraindications

• Severe hepatic impairmentOrganHighLiver function concerns
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Severe myelosuppressionHematologicHigh
• Severe bone marrow suppressionHematologicHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• HypotensionCardiovascularUncommonLow blood pressure
• Nausea/vomitingGastrointestinalCommon
• Nausea and vomitingGastrointestinalCommon
• NeutropeniaHematologicCommonLow neutrophil count
• MucositisGastrointestinal / MucosalUncommon
• MyelosuppressionHematologicCommon
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers

Drug Interactions

• CYP3A4 inhibitorsLow
• Other myelosuppressive agentsHigh
• DNA-intercalating agents (e.g., anthracyclines)High

Population Constraints

• Renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Patients with pre-existing bone marrow suppressionHematologicAbsolute
• Pregnant womenReproductiveAbsolute

Regulatory Status

• European UnionInvestigationalClinical trial authorization only.
• United StatesInvestigationalInvestigational New Drug (IND) status only.
• United KingdomUnapprovedNo MHRA approval; used only in research or historical clinical trials

No FDA or EMA approval; used only in research and early clinical studies.

Evidence & Sources

• Recent developments in bisintercalator natural products
  Journal ArticleModerateZolova OE, Mady AS, Garneau-Tsodikova S2010-01-01T00:00:00.000000Z
• Echinomycin biosynthesis
  Journal ArticleModerateSato M, et al.2013-01-01T00:00:00.000000Z
• Advances in Peptide-based DNA/RNA-Intercalators
  Journal ArticleModerateMatić J, et al.2016-01-01T00:00:00.000000Z
• Echinomycin: the first bifunctional intercalating agent in clinical trials
  Journal ArticleModerateFoster BJ, et al.1985-01-01T00:00:00.000000Z
• Cancer therapeutic agents targeting hypoxia-inducible factor-1
  Journal ArticleModerateWang R, Zhou S, Li S2011-01-01T00:00:00.000000Z

Frequently Asked Questions